Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 16/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5126333 | 0.92 | KDM4E (0.46) | BDKRB1KDM4EHSD17B10ADRB2TSHR | |
| SCHEMBL5128553 | 0.88 | BDKRB1 (0.39) | BDKRB1HSD17B10TSHRALDH1A1 | |
| SCHEMBL5125430 | 0.87 | BDKRB1 (0.42) | BDKRB1KDM4EHSD17B10TSHRMAPK1 | |
| SCHEMBL5126182 | 0.86 | BDKRB1 (0.46) | BDKRB1KDM4EHSD17B10TSHRMAPK1 | |
| SCHEMBL5128655 | 0.86 | TSHR (0.46) | BDKRB1KDM4EHSD17B10TSHRMAPK1 | |
| SCHEMBL5131514 | 0.85 | BDKRB1 (0.45) | BDKRB1 | |
| SCHEMBL5131951 | 0.85 | BDKRB1 (0.47) | BDKRB1KDM4EHSD17B10ADRB2TSHR | |
| SCHEMBL5125344 | 0.84 | BDKRB1 (0.46) | BDKRB1 | |
| SCHEMBL3821979 | 0.82 | DRD2 (0.46) | BDKRB1KDM4EADRB2KMT2A | |
| SCHEMBL3822103 | 0.81 | BDKRB1 (0.47) | BDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580965-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-11-12 | — | — | US | claimed |
| US-20080249128-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2008-10-09 | — | — | US | claimed |
| US-8580965-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-20080249128-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249128-A1 | Substituted Sulfonamide Compounds | BDKRB1, BDKRB2, NPSR1 | BDKRB1 1/4885KDM4E 4132/4885HSD17B10 4591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.